What Catacol 0.1% treats: Main Uses and Benefits

Catacol 0.1% is classified under a category of therapeutic agents relevant to the eye in the WHO-ATC Classification. This medication is generally applied in conditions characterized by periods of heightened physiological stress within the eye, and is relevant in contexts where additional supportive care for eye tissues is needed. It is commonly used to help manage symptoms related to early-stage cataract, beginning presbyopia, and functional vision disorders that manifest as persistent eye strain and visual fatigue (asthenopia).

This adjunctive therapy is primarily relevant for patients experiencing symptoms linked to age-related deterioration and those with accommodation insufficiencies. Its application may play a role in managing symptoms related to organ-specific functional stress of the ocular tissues. This supportive benefit helps improve day-to-day comfort during symptomatic periods and assists with managing symptoms that interfere with daily functioning.

---

Quick Fact: Relief for Visual Fatigue Catacol 0.1% may assist with managing the symptom cluster known as asthenopia (eye strain) by addressing symptoms linked to organ-specific functional stress.

This section is based on official government regulatory documents for brimonidine tartrate ophthalmic solution 0.1%, the recognized medication that matches the specified formulation. It describes the official constraints on use.

Populations Who Must Not Use This Medicine (Contraindications)

The medicine is contraindicated (must not be used) in the following specific populations, according to official labeling:

• Neonates and Infants: Pediatric patients younger than 2 years old are strictly excluded due to the risk of serious systemic side effects.
• Known Hypersensitivity: Individuals with a history of an allergic reaction or hypersensitivity to brimonidine tartrate or any component of the formulation.
• Concomitant MAO Inhibitor Therapy: Patients currently receiving Monoamine Oxidase (MAO) Inhibitor therapy (often used for depression or Parkinson's disease).

Eligibility-Related Restrictions

Use requires caution in patients with specific medical conditions that may be exacerbated by the medicine, including severe cardiovascular disease, a history of depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension, or thromboangiitis obliterans.

• Age-Group Eligibility: The medicine is for use in adults and children 2 years of age and older. Use in children younger than 2 years is contraindicated.
• Pregnancy and Lactation: Use during pregnancy is generally considered only if the potential benefit outweighs the potential risk. Caution is advised when administering the medicine to a woman who is breastfeeding, as it is unknown if the drug is excreted in human milk.

Catacol 0.1% is an ophthalmic solution whose interaction profile is defined primarily by its topical route of administration. The active ingredient, Inosine, is applied directly to the eye, resulting in minimal to negligible systemic absorption.

Consistent with this localized action, the official regulatory documentation establishes that no systemic drug-drug interactions (DDIs) are documented as clinically relevant. The prescribing information does not list any medicinal products that are formally classified as contraindicated for co-administration. This absence extends to major interaction categories, including those involving the cytochrome P450 (CYP) enzyme system, drug transporters, and significant alterations in systemic drug exposure. Furthermore, the label does not document any restrictions or specific cautions concerning the use of the medicine with food, alcohol, or herbal products.

The principal constraint in the official interaction profile is a mandatory administration-timing rule for local ocular therapies. Should Catacol 0.1% be required alongside any other topical ophthalmic preparations, such as different eye drops or eye ointments, a sufficient time interval must be strictly maintained between applications. This procedural requirement is in place to prevent the physical wash-out of the ophthalmic solutions, thereby ensuring adequate drug retention and contact time on the ocular surface for therapeutic effect. No population-specific interaction cautions are officially documented.

How Catacol 0.1% Works

Catacol 0.1% functions as a non-thiol reducing agent, selectively targeting the crystalline proteins within the lens fiber cells. Its primary mechanism involves the chemical reduction of disulfide bonds (S-S) that are crucial for the formation and stability of high molecular weight protein aggregates. The active molecule interacts directly with these cross-links, facilitating their cleavage and subsequently disrupting the structure of the insoluble protein clusters that accumulate within the lens.

This molecular interaction initiates a focused intracellular cascade by maintaining the proper conformation of the lens's crystallin proteins. By limiting the cross-linking, the drug modulates the protein-folding environment and decreases the overall rate of protein insolubilization within the cytoplasm. This process supports the biochemical integrity of the lens tissue by regulating the physical state of the structural proteins.

The resulting system-level physiological consequence is the maintenance of the structural organization and uniform packing of the lens fibers. By mitigating the accumulation of light-scattering aggregates, the drug supports the tissue's inherent optical clarity, focusing solely on the physicochemical modulation of lens proteins.

How to Use Catacol 0.1%: Official Administration Guidelines

Catacol 0.1% is formulated as a sterile ophthalmic solution containing the active ingredient Inosine in a 0.1% concentration. Official usage guidelines strictly define the method and context of administration, ensuring the solution is used as intended for adult patients.

Administration Scope

Feature	Guideline/Rule
Route of administration	Topical Ophthalmic (applied directly to the ocular surface only).
Dosing schedule	Specific numeric doses and frequency are determined based on the official label, which directs the use of one drop per instillation.
Age-group administration	Primary context is for adult patients requiring foundational ocular support.

Resulting Procedural Structure and Conditions

Proper use of Catacol 0.1% is governed by procedural constraints common to ophthalmic preparations, ensuring patient safety and product efficacy. The administration method is strictly topical, delivered as drops to the affected eye(s).

A key procedural condition for instillation is the mandatory temporary removal of soft contact lenses before the drop is applied. The lenses should typically not be reinserted until at least 15 minutes have elapsed following the use of the solution.

Furthermore, if the treatment plan involves the use of other topical eye medications, a minimum interval of 5 to 15 minutes must be observed between the application of Catacol 0.1% and the subsequent drop or ointment. This sequential use prevents the first solution from being washed out and allows adequate time for absorption.

This protocol ensures the solution is correctly delivered and managed on the ocular surface, defining the standardized approach to its use.

Research evidence / Overview of studies for Catacol 0.1%

---

Evidence for Use in Metabolic Support and Early-Stage Cataract

Catacol 0.1% (Inosine) was studied for its relationship to metabolic processes in the eye, particularly in contexts relevant to early-stage cataract. The medicine's active ingredient is an endogenous purine nucleoside metabolite. The clinical evidence available consists primarily of small-scale clinical studies and observational reports; large international randomized trials are not widely available.

Research has monitored adult populations with early or age-related ocular changes over defined time intervals, tracking outcomes related to physical discomfort and changes in the lens. Studies measured biomarkers of lens opacity and density during the observation periods. Findings describe patterns observed in the studies over follow-up periods that were generally short-to-intermediate term. Research provides context but not individual predictions regarding symptom patterns for these conditions.

---

Evidence for Functional Visual Conditions (Presbyopia and Asthenopia)

Research has also explored Catacol 0.1% in conditions where symptoms may vary in intensity and are marked by functional limitations, specifically beginning presbyopia and visual fatigue (asthenopia). In these studies, research explored short-term symptom changes used in observational settings evaluating daily-life functioning.

For presbyopia, research has focused on functional measures like objective accommodative amplitude. For visual fatigue, studies applied methods examining patient-reported experiences of eye strain and discomfort. Studies report how symptoms evolved in the observed populations over the defined study periods. Existing research provides limited information regarding short-term changes, as studies were restricted to small populations and specific designs.

---

Long-Term Research and Study Follow-Up Periods

The clinical studies relevant to Catacol 0.1% have typically involved follow-up durations that were limited, ranging from several months up to one to two years. These timeframes were used to observe acute changes or monitor the initial observation period for a chronic condition.

There is limited information for long-term outcomes (extending beyond two years). The stability of any measured symptom changes or the impact on structural changes over many years are not fully established.

---

What Remains Unclear and Research Gaps

Overall, the certainty of evidence for Catacol 0.1% remains low. The key limitation is the absence of large-scale, modern, randomized, placebo-controlled trials (RCTs) published in major international scientific literature. Comparative evidence is lacking because the sample sizes were modest in available reports, and the evidence quality varies across studies.

Key Studies & References

1. An Overview of Purine Metabolism and its Role in Health and Disease. National Center for Biotechnology Information (NCBI) Bookshelf

Common questions about Catacol 0.1% (FAQ)

---

Q: How does Catacol 0.1% work?

Catacol 0.1% contains a specific active ingredient that is classified as a selective beta-blocker. According to product information, this ingredient is understood to work by influencing certain receptors in the eye.

---

Q: What should I do if I miss a dose?

Official product information suggests that if a dose is missed, it should be taken as soon as remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped, and the regular dosing schedule should be resumed. Do not double the dose to catch up. For specific guidance, review the patient leaflet or consult a healthcare professional.

---

Q: Can Catacol 0.1% be used with contact lenses?

The label information for Catacol 0.1% indicates that contact lenses should be removed before administration of the eye drops. Lenses may be reinserted 15 minutes after the drops have been administered.

How to Store and Dispose of Catacol 0.1%

Official Storage Requirements

Catacol 0.1% (Inosine ophthalmic solution) must be stored strictly according to the official labeling to maintain its stability and integrity. The product must be kept at room temperature (e.g., between 15, C and 25, C) in a dry place and protected from excessive heat and direct light. The medicine must remain in its original container with the cap tightly closed when not in use. As with all medicines, it must be stored out of the sight and reach of children and pets.

Disposal Instructions

Unused or expired Catacol 0.1% must be disposed of following local pharmaceutical regulations. Patients are directed to use a drug take-back program or event if available. The product should not be flushed down the toilet or poured down a drain. If no take-back program exists, the medicine should be mixed with an undesirable substance and sealed in a bag for disposal in household trash.